טוען...
Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness
Inflammatory chemokines are instrumental players in cancer-related inflammation contributing to numerous steps during tumor progression. In Kaposi's sarcoma, we have found that downregulation of the atypical chemokine receptor 2 (ACKR2) by the KRAS/BRAF/ERK pathway profoundly affects the tumor...
שמור ב:
| הוצא לאור ב: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4353167/ https://ncbi.nlm.nih.gov/pubmed/25964861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/21624011.2014.955337 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|